UCLA Health is a health system which comprises a number of hospitals, the David Geffen School of Medicine at UCLA and an extensive primary care network in the Los Angeles region. As a regional health provider, it benefits from the academic affiliation offered by the UCLA campus, as this increases its status in the medical marketplace.[citation needed] For instance, the symbiotic relationship with the campus allowed the creation of nominal assistant professor-level appointments for primary care physicians, but this practice has now[when?] been limited because of opposition from the academic community. In 2007, UCLA Health founded Operation Mend, a program for treating military veterans who were wounded in wars in Iraq and Afghanistan. In 2016 Operation Mend received a grant from Wounded Warrior Project to expand its offering to include PTSD treatment and became part of the Warrior Care Network.A 2013 report by the California State Auditor has suggested that the financial transactions from the health system to the medical school, which have grown threefold over the reporting period, deserve more transparency. A study by the Rand Corporation about leadership structures at UCLA Health again addresses the ambiguous position of UCLA Health as both an academic and a commercial entity. More recently,[when?] the UCOP has scheduled a bylaw amendment for the Committee on Health Services with a view to change the composition of the leadership structure to enable the UCLA Health System (then so called) to compete and collaborate more effectively in the health services marketplace.The governance structure includes a non-fiduciary Board of Overseers and a Community Engagement Committee that is made up of faculty and staff and reports to the Vice Chancellor, Health Sciences. In addition there is a UCLA Health Sustainability Steering Committee.Budgetary information for bondholders (2013) and the 2014–2015 Financial Report are available through the University of California Office of the President..
Abstract To assess the role of the serum and glucocorticoid-regulated kinase (SGK) kinase in multiple myeloma, we ectopically expressed wild type or a phosphomimetic version of SGK into multiple myeloma cell lines. These cells were specifically resistant to the ER stress inducers tunicamycin, thapsigargin, and bortezomib. In contrast, there was no alteration of sensitivity to dexamethasone, serum starvation, or mTORC inhibitors. Mining of genomic data from a public database indicated that low baseline SGK expression in multiple myeloma patients correlated with enhanced ability to undergo a complete response to subsequent bortezomib treatment and a longer time to progression and overall survival following treatment. SGK overexpressing multiple myeloma cells were also relatively resistant to bortezomib in a murine xenograft model. Parental/control multiple myeloma cells demonstrated a rapid upregulation of SGK expression and activity (phosphorylation of NDRG-1) during exposure to bortezomib and an SGK inhibitor significantly enhanced bortezomib-induced apoptosis in cell lines and primary multiple myeloma cells. In addition, a multiple myeloma cell line selected for bortezomib resistance demonstrated enhanced SGK expression and SGK activity. Mechanistically, SGK overexpression constrained an ER stress–induced JNK proapoptotic pathway and experiments with a SEK mutant supported the notion that SGK's protection against bortezomib was mediated via its phosphorylation of SEK (MAP2K4) which abated SEK/JNK signaling. These data support a role for SGK inhibitors in the clinical setting for myeloma patients receiving treatment with ER stress inducers like bortezomib. Implications: Enhanced SGK expression and activity in multiple myeloma cells contributes to resistance to ER stress, including bortezomib challenge. Mol Cancer Res; 14(4); 397–407. ©2016 AACR.
Background Gender equity in surgery remains an ongoing focus of investigation and while there are more women entering the surgical oncology workforce, disparities persist. Professional surgical organizations, such as the Society of Surgical Oncology (SSO), are powerful engines for scientific advancement and career growth. The objective of this study was to evaluate contemporary trends in gender representation related to active participation and leadership within the SSO. Materials and Methods Data were obtained from the SSO database and website that included all membership, committee membership, and leadership roles as well as annual meeting program information from 2010 to 2025. Gender of individuals was determined by self-report or from institutional websites. Data were analyzed using descriptive statistics including logistic regression and two-way analysis of variance (ANOVA). Results From 2010 to 2024, there was a significant increase in female committee membership, with women comprising 49.3% of members in 2024, up from 25.5% in 2010 (p < 0.001). Female representation was noted in relation to committee leadership with an increase from 2010, where women comprised 20.3% of leadership roles, to an increase of 48.1% in 2024 (p < 0.01). From 2013 to 2025, there was an overall increase in female SSO meeting presenters from 38.8% in 2013 to 44.4% in 2025 (p = 0.018). Conclusions Representation of women within the SSO membership, committee leadership, and presenters at the annual meeting has increased from 2010 to 2025. This finding reflects both broader societal advances towards inclusivity as well as the SSO's ongoing efforts in working toward promoting career development for all members.
This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia. Formal consensus was reached for 150 (75%) of 199 statements. Strong agreement was observed between interventional and surgical oncologists, with only 12 (6%) of 199 statements showing significantly different ratings. Participants agreed that ablation margins should be assessed and documented for every treated tumour. Margins should be assessed quantitatively in three dimensions, with contrast-enhanced CT or MRI, preferably intraprocedurally with ablation confirmation software. Ablation margins should be categorised as A0 (tumour completely covered with sufficient margin), A1 (tumour completely covered but insufficient margin), or A2 (portion of tumour remains unablated). This effort is, to our knowledge, the first international consensus initiative to define best-practice recommendations for margin assessment in liver tumour thermal ablation to standardise practices, aiming to improve and promote uniform outcomes.
Although fall prevention programs in real-world clinical settings often generate recommendations to reduce fall risk factors, evidence that they improve clinical outcomes remains limited. To better understand this gap, we examined implementation rates of recommendations. This retrospective cohort study evaluated patients who received care at an interdisciplinary (nurse, physical therapist, geriatrician) fall prevention consultation clinic from November 2020 to December 2022. Data were collected on patient demographics, screening assessments (including self-reported falls, fracture risk, visual acuity, cognition, and orthostatic blood pressure), physical therapy evaluations, and implementation of recommendations. Fall- and fracture-related ED visits and hospitalizations in the year before and after the clinic visit were compared. Ninety-four patients seen with a mean age of 79 years (SD = 8.4, range 63–101); 71
